TY - JOUR
T1 - SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity
AU - Aguilar-Bretones, Muriel
AU - den Hartog, Yvette
AU - van Dijk, Laura L.A.
AU - Malahe, S. Reshwan K.
AU - Dieterich, Marjolein
AU - Mora, Héctor Tejeda
AU - Mueller, Yvonne M.
AU - Koopmans, Marion P.G.
AU - Reinders, Marlies E.J.
AU - Baan, Carla C.
AU - van Nierop, Gijsbert P.
AU - de Vries, Rory D.
AU - Abrahams, Alferso C.
AU - Baas, Marije C.
AU - Hemmelder, Marc H.
AU - Bouwmans, Pim
AU - ten Dam, Marc A.G.J.
AU - Gommers, Lennert
AU - de Vries, Aiko P.J.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/5/28
Y1 - 2024/5/28
N2 - Healthy individuals with hybrid immunity, due to a SARS-CoV-2 infection prior to first vaccination, have stronger immune responses compared to those who were exclusively vaccinated. However, little is known about the characteristics of antibody, B- and T-cell responses in kidney disease patients with hybrid immunity. Here, we explored differences between kidney disease patients and controls with hybrid immunity after asymptomatic or mild coronavirus disease-2019 (COVID-19). We studied the kinetics, magnitude, breadth and phenotype of SARS-CoV-2-specific immune responses against primary mRNA-1273 vaccination in patients with chronic kidney disease or on dialysis, kidney transplant recipients, and controls with hybrid immunity. Although vaccination alone is less immunogenic in kidney disease patients, mRNA-1273 induced a robust immune response in patients with prior SARS-CoV-2 infection. In contrast, kidney disease patients with hybrid immunity develop SARS-CoV-2 antibody, B- and T-cell responses that are equally strong or stronger than controls. Phenotypic analysis showed that Spike (S)-specific B-cells varied between groups in lymph node-homing and memory phenotypes, yet S-specific T-cell responses were phenotypically consistent across groups. The heterogeneity amongst immune responses in hybrid immune kidney patients warrants further studies in larger cohorts to unravel markers of long-term protection that can be used for the design of targeted vaccine regimens.
AB - Healthy individuals with hybrid immunity, due to a SARS-CoV-2 infection prior to first vaccination, have stronger immune responses compared to those who were exclusively vaccinated. However, little is known about the characteristics of antibody, B- and T-cell responses in kidney disease patients with hybrid immunity. Here, we explored differences between kidney disease patients and controls with hybrid immunity after asymptomatic or mild coronavirus disease-2019 (COVID-19). We studied the kinetics, magnitude, breadth and phenotype of SARS-CoV-2-specific immune responses against primary mRNA-1273 vaccination in patients with chronic kidney disease or on dialysis, kidney transplant recipients, and controls with hybrid immunity. Although vaccination alone is less immunogenic in kidney disease patients, mRNA-1273 induced a robust immune response in patients with prior SARS-CoV-2 infection. In contrast, kidney disease patients with hybrid immunity develop SARS-CoV-2 antibody, B- and T-cell responses that are equally strong or stronger than controls. Phenotypic analysis showed that Spike (S)-specific B-cells varied between groups in lymph node-homing and memory phenotypes, yet S-specific T-cell responses were phenotypically consistent across groups. The heterogeneity amongst immune responses in hybrid immune kidney patients warrants further studies in larger cohorts to unravel markers of long-term protection that can be used for the design of targeted vaccine regimens.
UR - https://www.scopus.com/pages/publications/85194889156
U2 - 10.1038/s41541-024-00886-0
DO - 10.1038/s41541-024-00886-0
M3 - Article
AN - SCOPUS:85194889156
VL - 9
JO - npj Vaccines
JF - npj Vaccines
IS - 1
M1 - 93
ER -